Magnolol induces apoptosis in osteosarcoma cells via G0/G1 phase arrest and p53-mediated mitochondrial pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Osteosarcoma is a primary bone cancer with high invasiveness.
• Magnolol exhibits known antitumor properties in various cancer cell lines.
• The specific effects of magnolol on human osteosarcoma cells remain largely uncharacterized.

Purpose of the Study:

• To investigate the antitumor activity of magnolol in human osteosarcoma cells (HOC).
• To elucidate the molecular mechanisms underlying magnolol's effects on HOC.

Main Methods:

• Assessed magnolol's impact on MG-63 and 143B osteosarcoma cell growth.
• Analyzed magnolol's effects on apoptosis and cell cycle progression.
• Investigated changes in pro- and anti-apoptotic protein expression.
• Utilized pifithrin-a (PFT-a), a p53 inhibitor, to explore the role of p53.

Main Results:

• Magnolol significantly inhibited the growth of MG-63 and 143B cells.
• Magnolol induced apoptosis and cell cycle arrest at the G0/G1 phase.
• Upregulation of pro-apoptotic proteins and downregulation of anti-apoptotic proteins were observed.
• Magnolol-induced apoptosis was significantly attenuated by pifithrin-a pretreatment.

Conclusions:

• Magnolol exhibits significant antitumor effects on human osteosarcoma cells.
• Magnolol induces apoptosis via G0/G1 phase arrest and the p53-mediated mitochondrial pathway.
• These findings suggest magnolol as a potential therapeutic agent for osteosarcoma.